Clinical Trials Directory

Trials / Terminated

TerminatedNCT00482040

Randomized Trial Investigating Four Nasal CPAP Systems in the Management of Apnea of Prematurity

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
16 (actual)
Sponsor
University Hospital Tuebingen · Academic / Other
Sex
All
Age
14 Weeks
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate four different nasal continuous pressure systems, which are usually applied on our neonatal intensive care unit, with regard of their effect on bradycardia and desaturations in preterm infants.

Detailed description

BACKGROUND: Apnea of prematurity (AOP) is a common problem in preterm infants. Nasal respiratory support using either Continuous Positive Airway Pressure (CPAP) or Intermittent Mandatory Ventilation (IMV) are, among others, widely used treatments. Which of the different systems is the most efficient, however, is unclear. OBJECTIVE: Efficiency of different CPAP systems on reducing the cumulative percentage of bradycardia and desaturation in preterm infants. METHODS: In a prospective, randomized, cross-over trial 32 preterm infants Infants will randomly allocated to receive nasal CPAP delivered by one of the following sys-tems: (1) a conventional IMV-System (Stephanie, Stephan GmbH, Germany with PIP 15 cmH2O, RR 10/min) delivering CPAP via short binasal prongs (Hudson RCI, USA); (2) the Infant-Flow-System (EME Ltd, Great Britain) with CPAP delivery via short binasal prongs; (3) the Infant-Flow-AdvanceTM-System used in the pressure assist mode with PIP 10 cmH2O, RR 10/min; and (4) a nasal underwater bubble CPAP with application via binasal prongs (Hudson RCI, USA). All systems will be adjusted to achieve an approximate PEEP of 6 cm H2O. Each study lasts 24 hours, during which chest wall and abdominal movements, SaO2, tcPCO2, ECG, esopha-gus pressure and CPAP-/IMV-pressure will be recorded continuously. Infants will be studied in room air in a 15° head tilt prone position while being treated with caffeine (3mg/kg/d). PRIMARY OUTCOME MEASURE Cumulative percentage of bradycardia (heart rate \<80/min) and desaturation (SaO2 \<80%) per hour.

Conditions

Interventions

TypeNameDescription
DEVICEStephanie (TM), Infant Flow (TM), Infant Flow advance (TM), Bubble CPAP

Timeline

Start date
2004-03-01
Completion
2006-01-01
First posted
2007-06-04
Last updated
2007-08-24

Source: ClinicalTrials.gov record NCT00482040. Inclusion in this directory is not an endorsement.